Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(4):531–537. doi: 10.1054/bjoc.2001.1960

Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis

M E M Oude Luttikhuis 1, J E Powell 2, S A Rees 1, T Genus 1, S Chughtai 1, P Ramani 3, J R Mann 4, C M McConville 1
PMCID: PMC2364087  PMID: 11506492

Abstract

Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prognostic potential in non-MYCN-amplified neuroblastomas, we looked for a correlation between clinical outcome and loss of heterozygosity (LOH) on four chromosomes that frequently show alteration in neuroblastoma (chromosomes 3, 4, 11 and 14). Chromosome 11q loss (with frequent parallel loss of chromosomes 3p, 4p and/or 14q) was found exclusively in tumours without MYCN amplification and was significantly associated with poor event-free survival. The 2-year event-free survival rate for 11q LOH cases was 30%, compared to 34% for MYCN-amplified cases and 100% for cases without these abnormalities. While 11q LOH was associated predominantly with advanced-stage disease, 2 cases with low-stage disease and 11q LOH both suffered relapses. We conclude that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Thus this genetic alteration may be an important new prognostic marker in neuroblastoma. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: neuroblastoma, LOH, chromosome 11, MYCN

Full Text

The Full Text of this article is available as a PDF (71.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bown N., Cotterill S., Lastowska M., O'Neill S., Pearson A. D., Plantaz D., Meddeb M., Danglot G., Brinkschmidt C., Christiansen H. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999 Jun 24;340(25):1954–1961. doi: 10.1056/NEJM199906243402504. [DOI] [PubMed] [Google Scholar]
  2. Brinkschmidt C., Poremba C., Christiansen H., Simon R., Schäfer K. L., Terpe H. J., Lampert F., Boecker W., Dockhorn-Dworniczak B. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer. 1998 Jun;77(12):2223–2229. doi: 10.1038/bjc.1998.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brodeur G. M., Maris J. M., Yamashiro D. J., Hogarty M. D., White P. S. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):93–101. doi: 10.1097/00043426-199703000-00001. [DOI] [PubMed] [Google Scholar]
  4. Brodeur G. M. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer. 1995;31A(4):505–510. doi: 10.1016/0959-8049(95)00040-p. [DOI] [PubMed] [Google Scholar]
  5. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  6. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol. 1995 Apr;24(4):215–221. doi: 10.1002/mpo.2950240402. [DOI] [PubMed] [Google Scholar]
  7. Caron H., Peter M., van Sluis P., Speleman F., de Kraker J., Laureys G., Michon J., Brugières L., Voûte P. A., Westerveld A. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet. 1995 Apr;4(4):535–539. doi: 10.1093/hmg/4.4.535. [DOI] [PubMed] [Google Scholar]
  8. Caron H., van Sluis P., Buschman R., Pereira do Tanque R., Maes P., Beks L., de Kraker J., Voûte P. A., Vergnaud G., Westerveld A. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum Genet. 1996 Jun;97(6):834–837. doi: 10.1007/BF02346199. [DOI] [PubMed] [Google Scholar]
  9. Cheng N. C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene. 1995 Jan 19;10(2):291–297. [PubMed] [Google Scholar]
  10. Ejeskär K., Aburatani H., Abrahamsson J., Kogner P., Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer. 1998 Jun;77(11):1787–1791. doi: 10.1038/bjc.1998.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fong C. T., Dracopoli N. C., White P. S., Merrill P. T., Griffith R. C., Housman D. E., Brodeur G. M. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A. 1989 May;86(10):3753–3757. doi: 10.1073/pnas.86.10.3753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fong C. T., White P. S., Peterson K., Sapienza C., Cavenee W. K., Kern S. E., Vogelstein B., Cantor A. B., Look A. T., Brodeur G. M. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992 Apr 1;52(7):1780–1785. [PubMed] [Google Scholar]
  13. Gehring M., Berthold F., Edler L., Schwab M., Amler L. C. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 1995 Nov 15;55(22):5366–5369. [PubMed] [Google Scholar]
  14. Guo C., White P. S., Hogarty M. D., Brodeur G. M., Gerbing R., Stram D. O., Maris J. M. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol. 2000 Dec;35(6):544–546. doi: 10.1002/1096-911x(20001201)35:6<544::aid-mpo10>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  15. Guo C., White P. S., Weiss M. J., Hogarty M. D., Thompson P. M., Stram D. O., Gerbing R., Matthay K. K., Seeger R. C., Brodeur G. M. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999 Sep 2;18(35):4948–4957. doi: 10.1038/sj.onc.1202887. [DOI] [PubMed] [Google Scholar]
  16. Hoshi M., Otagiri N., Shiwaku H. O., Asakawa S., Shimizu N., Kaneko Y., Ohi R., Hayashi Y., Horii A. Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss. Br J Cancer. 2000 Jun;82(11):1801–1807. doi: 10.1054/bjoc.2000.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kerbl R., Urban C. E., Lackner H., Höfler G., Ambros I. M., Ratschek M., Ambros P. F. Connatal localized neuroblastoma. The case to delay treatment. Cancer. 1996 Apr 1;77(7):1395–1401. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1395::AID-CNCR26>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  18. Lastowska M., Nacheva E., McGuckin A., Curtis A., Grace C., Pearson A., Bown N. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Genes Chromosomes Cancer. 1997 Mar;18(3):162–169. [PubMed] [Google Scholar]
  19. Maris J. M., White P. S., Beltinger C. P., Sulman E. P., Castleberry R. P., Shuster J. J., Look A. T., Brodeur G. M. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 1995 Oct 15;55(20):4664–4669. [PubMed] [Google Scholar]
  20. Mora J., Cheung N. K., Kushner B. H., LaQuaglia M. P., Kramer K., Fazzari M., Heller G., Chen L., Gerald W. L. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn. 2000 Feb;2(1):37–46. doi: 10.1016/S1525-1578(10)60613-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Powell J. E., Estève J., Mann J. R., Parker L., Frappaz D., Michaelis J., Kerbl R., Mutz I. D., Stiller C. A. Neuroblastoma in Europe: differences in the pattern of disease in the UK. SENSE. Study group for the Evaluation of Neuroblastoma Screening in Europe. Lancet. 1998 Aug 29;352(9129):682–687. doi: 10.1016/s0140-6736(97)11239-9. [DOI] [PubMed] [Google Scholar]
  22. Schleiermacher G., Delattre O., Peter M., Mosseri V., Delonlay P., Vielh P., Thomas G., Zucker J. M., Magdelénat H., Michon J. Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: a single-institution study. Int J Cancer. 1996 Apr 22;69(2):73–78. doi: 10.1002/(SICI)1097-0215(19960422)69:2<73::AID-IJC1>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  23. Schleiermacher G., Peter M., Michon J., Hugot J. P., Vielh P., Zucker J. M., Magdelénat H., Thomas G., Delattre O. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer. 1994 Aug;10(4):275–281. doi: 10.1002/gcc.2870100409. [DOI] [PubMed] [Google Scholar]
  24. Srivatsan E. S., Ying K. L., Seeger R. C. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer. 1993 May;7(1):32–37. doi: 10.1002/gcc.2870070106. [DOI] [PubMed] [Google Scholar]
  25. Suzuki T., Yokota J., Mugishima H., Okabe I., Ookuni M., Sugimura T., Terada M. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res. 1989 Mar 1;49(5):1095–1098. [PubMed] [Google Scholar]
  26. Takayama H., Suzuki T., Mugishima H., Fujisawa T., Ookuni M., Schwab M., Gehring M., Nakamura Y., Sugimura T., Terada M. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene. 1992 Jun;7(6):1185–1189. [PubMed] [Google Scholar]
  27. Takeda O., Homma C., Maseki N., Sakurai M., Kanda N., Schwab M., Nakamura Y., Kaneko Y. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer. 1994 May;10(1):30–39. doi: 10.1002/gcc.2870100106. [DOI] [PubMed] [Google Scholar]
  28. Theobald M., Christiansen H., Schmidt A., Melekian B., Wolkewitz N., Christiansen N. M., Brinkschmidt C., Berthold F., Lampert F. Sublocalization of putative tumor suppressor gene loci on chromosome arm 14q in neuroblastoma. Genes Chromosomes Cancer. 1999 Sep;26(1):40–46. [PubMed] [Google Scholar]
  29. Vandesompele J., Van Roy N., Van Gele M., Laureys G., Ambros P., Heimann P., Devalck C., Schuuring E., Brock P., Otten J. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998 Oct;23(2):141–152. doi: 10.1002/(sici)1098-2264(199810)23:2<141::aid-gcc7>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  30. Yu S., Yu D., Hainline B. E., Brener J. L., Wilson K. A., Wilson L. C., Oude-Luttikhuis M. E., Trembath R. C., Weinstein L. S. A deletion hot-spot in exon 7 of the Gs alpha gene (GNAS1) in patients with Albright hereditary osteodystrophy. Hum Mol Genet. 1995 Oct;4(10):2001–2002. doi: 10.1093/hmg/4.10.2001. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES